ORCHARD PARK, N.Y., June 9 MINRAD International,Inc. (Amex: BUF) today announced it has received approval from the U.S. Foodand Drug Administration Center for Veterinary Medicine to market Petrem(TM)(Sevoflurane) inhalation anesthetic. This week they have initiated their USproduct launch to the veterinary market.
About the Company
MINRAD International, Inc. is an interventional pain management companywith real-time image guidance and anesthesia and analgesia product lines. Thereal-time image guidance products facilitate minimally invasive surgeryespecially for pain management and have broad applications in orthopedics,neurosurgery, and interventional radiology. These devices enable medicalprofessionals to improve the accuracy of interventional procedures and reduceradiation exposure. MINRAD International also manufactures and markets genericinhalation anesthetics for use in connection with human and veterinarysurgical procedures. The company is developing a drug/drug delivery system forconscious sedation, which, similar to nitrous oxide in dental surgery,provides a patient with pain relief without loss of consciousness. Additionalinformation can be found at the company's website, http://www.minrad.com.
The information contained in this news release, other than historicalinformation, consists of forward-looking statements within the meaning of thePrivate Securities Litigation Reform Act of 1995. These statements may involverisks and uncertainties that could cause actual results to differ materiallyfrom those described in such statements. Factors that may cause actual resultsto differ materially from those expressed or implied by its forward-lookingstatements include, but are not limited to, Minrad International's limitedoperating history and business development associated with being a growthstage company; its dependence on key personnel; its need to attract and retaintechnical and managerial personnel; its ability to execute its businessstrategy; the intense competition it faces; its ability to protect itsintellectual property and proprietary technologies; its exposure to productliability claims resulting from the use of its products; general economic andcapital market conditions; financial conditions of its customers and theirperception of its financial condition relative to that of its competitors; aswell as those risks described under the heading "Risk Factors" of MinradInternational's Form 10-KSB-A, filed with the Securities and ExchangeCommission on April 21, 2008.. Although Minrad International, Inc. believesthat the expectations reflected in such forward-looking statements arereasonable, it can give no assurance that such expectations will prove to havebeen correct.CONTACT: Charles R. Trego, Jr. Executive Vice President and CFO E-mail: [email protected]
SOURCE MINRAD International, Inc.